Iris Grossman, Phd Email and Phone Number
Iris Grossman, Phd work email
- Valid
- Valid
- Valid
Iris Grossman, Phd personal email
I am a strategic leader with >20 years of Big Pharma and start-up biotech experience, leveraging Personalized Medicine approaches across the continuum of discovery, development and market positioning. Deeply rooted in science and analytics, I leverage my medical sciences, human genetics and Digi-/bio-marker training, to devise corporate strategies, multi-year partnerships and effective IP-backed value propositions. Portfolios managed span a wide variety of therapeutic areas, with particular emphasis on neurological diseases, autoimmunity and metabolic diseases. I have repeatedly built and developed high performing multi-disciplinary groups of experimentalists, data scientists, clinicians and pharmacologists. Collaboratively, these teams have consistently delivered high quality therapeutic and/or diagnostic results, utilizing cutting-edge innovation within a patient-centric culture.
Eleven Therapeutics
View-
Chief Therapeutics OfficerEleven Therapeutics May 2022 - PresentCambridge, GbChampion, supervise and manage the realization of Eleven's technology platforms into therapeutic assets (payloads and/or delivery vehicles) in the RNAi space, including R&D activities (Lead Selection & Optimization through to advanced clinical phases), IP and BD (partnerships and fundraising)
-
Chief Strategy Officer (Cso)Eleven Therapeutics Sep 2021 - Jul 2022Cambridge, Gb
-
Founding Advisor, Sab MemberEleven Therapeutics Apr 2020 - Aug 2021Cambridge, Gb
-
Strategic Founder AdvisorModulight.Bio Jul 2022 - Present#ModuLight.bio develops life transforming medicines against devastating neurological disorders, such as drug-resistant focal Epilepsy, Parkinson’s disease, and severe neuropathic pain syndromes, by harnessing next-generation optogenetic solutions.
-
Co-Founder And PresidentGross Advantage (Formerly Isragene) Nov 2007 - PresentGROSS Advantage (formerly IsraGene) is a therapeutic strategy consultancy, serving the continuum of drug and diagnostic R&D, leveraging principles of human genetics, pharmacogenomics, biomarkers and digital-markers. GROSS Advantage is dedicated to the successful discovery and development of drugs worldwide, with a specific focus on the smooth and effective pursuit of Personalized Medicine, from novel indication and target ID through to drug/Dx R&D clinical trials. The company serves a wide-range of clients (VCs, Big Pharma, biotech and non-for-profits), providing a range of services that converge into cost-effective applications at every stage of the R&D pipeline. Particular expertise in bridging gaps between Israeli inventions/capabilities and global requirements/partners.
-
Chairwoman, SabBc Platforms Jan 2023 - Dec 2024Zurich, Zurich, Ch -
Sab MemberBc Platforms Oct 2018 - Dec 2024Zurich, Zurich, ChBC Platforms is a world leader in providing powerful genomic data management and analysis solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and healthcare information technologies. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize decision making in drug development to bring clinical benefits to patients. With twenty years of experience, BC Platforms truly is an expert in understanding the science of life.
-
Chief Scientific Officer (Acting)Amide Technologies Oct 2020 - Sep 2021Cambridge, Massachusetts, UsAmide is at the forefront of a new biotech industry—fully synthetic proteins—thatboasts the combinatorial flexibility of small molecules, alongside the physiologicaladvantages of biologics. As the experts in this new field, we champion the proteintherapeutic 2.0 market.Amide was founded on the seminal inventions of Prof. Brad Pentelute enabling on-demandprotein synthesis including non-canonical chemical modifications - providingunique protein functionality (affinity, stability, bioavailability, cell membrane penetration)and reduced immunogenicity. Engineered synthetic proteins are coupled with ourartificial intelligence (AI) tools to predict performance characteristics of our assets at ascale unattainable with traditional methods for protein synthesis and post-translationalmodifications. -
Chief Scientific OfficerCamp4 Therapeutics Apr 2018 - Jun 2020Cambridge, Massachusetts, UsAs CSO I served as the scientific face of the company, effectively leading, creating, and communicating R&D strategies across the scope of discovery and development activities and collaborations.CAMP4 Solves the riddle of gene regulation in order to develop effective and safe therapeutics. We discover and harness the mechanisms by which human cells respond to their environment through genomic output. CAMP4’s proprietary Gene Circuitry Platform rapidly predicts and validates druggable targets that affect a broad spectrum of therapeutic areas, including metabolic, kidney, muscle, neurological diseases and others. -
Vp, Head Of Early Stage Clinical Development, Global R&DTeva Pharmaceuticals Aug 2017 - Mar 2018Tel-Aviv, IlTuning drug discovery and development to the voices of patients, physicians and disease/therapy, ESD incorporates key functions that innovatively and creatively coordinates the right inputs as early as possible along the R&D pipeline: clinical pharmacology and pharmacometrics, personalized and predictive medicine, analytics and big data, translational development and a patient officer. -
Vice President, Head Of Personalized & Predictive Medicine, Analytics And Big DataTeva Pharmaceuticals Sep 2015 - Jul 2017Tel-Aviv, IlEmploying cutting-edge biomarker research and Big Data analytics to innovatively inform and drive decision making that improves the benefit-risk profile of specialty, generic and technology offerings for patients, healthcare providers and payers. The unit generates strategic, evidence-based insight that informs Teva's entire pipeline, from discovery, through developmeny and into the market place.
-
Vice President, Global Head Of Personal Medicine And PharmacogenomicsTeva Pharmaceuticals Nov 2014 - Aug 2015Tel-Aviv, IlThe PMP unit is in charge of integrating biomarker research and treatment personalization into Teva's pipeline where a clear value-added proposition can offer patients and healthcare providers a clinically meaningful benefit/risk profile improvement. We support specialty and generic/repositioning pipelines through rigorous science and robust infrastructure, instilled when I joined the company and initiated this unit.
-
Sr. Director, Global Head Of Personalized Medicine And PharmacogenomicsTeva Pharmaceuticals May 2013 - Oct 2014Tel-Aviv, Il
-
Member, Board Of AdvisorsZinfandel Pharmaceuticals 2010 - May 2013
-
Director, Pharmacogenetics ConsultancyCabernet Pharmaceuticals Dec 2008 - Sep 2011Cabernet Pharmaceuticals is a pharmacogenetics and project-management consultancy committed to helping its clients develop drugs with a greater chance of success.Our consultants bring deep experience in pharmacogenetics (PGx) to improving R&D pipeline management, securing regulatory approval, and enhancing market acceptance. The consultancy relationship, together with our service-provider partnerships, affords a flexible resource to meet the dynamic needs of pharmaceutical and biotechnology companies, clinical-research and managed-healthcare organizations, and academic institutions. Together with our clients, we strive to exploit the predictive power of PGx to deliver the right medicine at the right dose to the right patient.
-
Pharmacogenetics ManagerGlaxosmithkline Apr 2007 - Dec 2008Brentford, Middlesex, GbPharmacogenetics lead for the Infectious Diseases therapeutic area, as well as program support for neurosciences and bio-pharmaceutics -
Pharmacogenetics ConsultantTeva Pharmaceuticals Mar 2005 - Mar 2007Tel-Aviv, Il
-
Research Associate - Population Genetics And PharmacogeneticsDuke University Mar 2005 - Mar 2007Durham, North Carolina, Us
Iris Grossman, Phd Skills
Iris Grossman, Phd Education Details
-
Technion - Israel Institute Of TechnologyMedicine / Pharmacogenetics -
The George Washington UniversityBusiness
-
Harvard Business SchoolExecutive Healthtech Program
-
Duke University School Of MedicineGenome Sciences/Genomics
-
Weizmann Institute Of SciencePharmacogenetics And Population Genetics
Frequently Asked Questions about Iris Grossman, Phd
What company does Iris Grossman, Phd work for?
Iris Grossman, Phd works for Eleven Therapeutics
What is Iris Grossman, Phd's role at the current company?
Iris Grossman, Phd's current role is Chief Therapeutics Officer (CTxO) at Eleven Therapeutics; Lead Pharmaceutical Science, Pipeline and Partnerships; Scientific Board Member and chair; serial Strategic Founder.
What is Iris Grossman, Phd's email address?
Iris Grossman, Phd's email address is ir****@****ene.com
What schools did Iris Grossman, Phd attend?
Iris Grossman, Phd attended Technion - Israel Institute Of Technology, The George Washington University, Harvard Business School, Duke University School Of Medicine, Weizmann Institute Of Science.
What are some of Iris Grossman, Phd's interests?
Iris Grossman, Phd has interest in Leadership, Pharmacogenetics, Rx/dx Co Development, Complex Traits, Population Genetics, Translational Medicine, Bioinformatics, Clinical Utility, Personalized Medicine, Clinical Trial Design.
What skills is Iris Grossman, Phd known for?
Iris Grossman, Phd has skills like Biotechnology, Clinical Trials, Pharmaceutical Industry, Drug Development, Life Sciences, Bioinformatics, Genomics, Neuroscience, Drug Discovery, Clinical Research, Molecular Biology, Translational Medicine.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial